physostigmine heptyl has been researched along with Acute Confusional Senile Dementia in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 11 (61.11) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Boido, V; Carotti, A; Catto, M; Giangreco, I; Nicolotti, O; Novelli, F; Pisani, L; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M | 1 |
| Andrisano, V; Bartolini, M; Belluti, F; Bisi, A; Di Marzo, V; Gobbi, S; Ligresti, A; Montanari, S; Mor, M; Rampa, A; Rivara, S; Scalvini, L | 1 |
| Li, X; Wang, S; Wang, Y; Wang, Z; Zhang, H | 1 |
| Rakonczay, Z | 1 |
| Chapin, D; Hubbard, ST; Jones, SB; Liston, DR; Nason, D; Nielsen, JA; Ramirez, A; Shalaby, IA; Villalobos, A; White, WF | 1 |
| Imbimbo, BP; Luzzana, M; Mosca, A; Onelli, E; Paleari, R; Rosti, E | 1 |
| Barchowsky, A; Block, GA; Cutler, NR; Reines, SA; Sawin, SF; Sramek, JJ | 1 |
| Cutler, NR; Sramek, JJ | 2 |
| Canal, N; Imbimbo, BP | 1 |
| Ghezzi, A; Imbimbo, BP; Luzzana, M; Mosca, A; Paleari, R | 1 |
| Alberoni, M; Imbimbo, BP; Lucca, U; Lucchelli, F; Thal, LJ | 1 |
| Calcagnini, G; Fieschi, C; Frontoni, M; Giubilei, F; Imbimbo, BP; Lino, S; Santini, M; Strano, S; Tisei, P | 1 |
| Scheltens, P; Verhey, FR | 1 |
| Imbimbo, BP; Lucca, U; Lucchelli, F; Martelli, P; Thal, LJ; Troetel, WM | 1 |
| Braida, D; Sala, M | 1 |
| Becker, RE; Hutt, V; Imbimbo, BP; Unni, LK | 1 |
| Brufani, M; Marta, M; Pomponi, M | 1 |
2 review(s) available for physostigmine heptyl and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Ligands | 2022 |
Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
Topics: Acetylcholine; Acetylcholinesterase; Activities of Daily Living; Agranulocytosis; Alzheimer Disease; Animals; Behavior, Animal; Biogenic Monoamines; Brain; Cholinesterase Inhibitors; Cognition Disorders; Erythrocytes; Humans; Learning; Memory; Physostigmine; Randomized Controlled Trials as Topic | 2001 |
6 trial(s) available for physostigmine heptyl and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.
Topics: Acetylcholinesterase; Adolescent; Adult; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Drug Monitoring; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Physostigmine; Reproducibility of Results | 1995 |
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Humans; Male; Middle Aged; Physostigmine; Placebos | 1995 |
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
Topics: Alzheimer Disease; Cholinergic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Physostigmine; Safety; Tacrine | 1995 |
Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Humans; Male; Middle Aged; Physostigmine | 1996 |
A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Physostigmine; Treatment Outcome | 1998 |
Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine; Treatment Outcome | 1999 |
10 other study(ies) available for physostigmine heptyl and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Crystallography, X-Ray; Dose-Response Relationship, Drug; Erythrocytes; Models, Molecular; Molecular Structure; Quinolizidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amidohydrolases; Butyrylcholinesterase; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2016 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Edrophonium; Humans; In Vitro Techniques; Phenylcarbamates; Physostigmine; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Humans; Indans; Male; Mice; Physostigmine; Piperidines; Rats; Rats, Sprague-Dawley; Tacrine | 2004 |
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dihydropyridines; Ethics, Medical; Humans; Nootropic Agents; Oximes; Physostigmine; Psychotropic Drugs; Pyridines; Tacrine; Thiadiazoles | 1995 |
Pharmacodynamic monitoring of eptastigmine in capillary blood.
Topics: Acetylcholinesterase; Adult; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Male; Middle Aged; Physostigmine; Time Factors | 1996 |
Cardiac autonomic dysfunction in patients with Alzheimer disease: possible pathogenetic mechanisms.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Autonomic Nervous System; Autonomic Nervous System Diseases; Cholinesterase Inhibitors; Electrocardiography; Erythrocytes; Female; Fourier Analysis; Heart; Heart Rate; Humans; Male; Middle Aged; Physostigmine; Signal Processing, Computer-Assisted | 1998 |
[Drugs for Alzheimer disease: what will the minister decide].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Approval; Female; Health Policy; Humans; Male; Middle Aged; Netherlands; Neurobehavioral Manifestations; Physostigmine; Religion and Medicine | 1998 |
Kinetics of cholinesterase inhibition by eptastigmine in man.
Topics: Adult; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Kinetics; Male; Physostigmine | 1991 |
Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Eels; In Vitro Techniques; Kinetics; Mathematics; Physostigmine | 1986 |